Naveen Pemmaraju: Our group’s newest paper just out in Blood Cancer Journal led by Dr. Danielle Hammond.

Naveen Pemmaraju recently shared on Twitter:

“Our group’s newest paper just out in Blood Cancer Journal led by Dr. Danielle Hammond. Response patterns and impact of MRD in IDH-m AML tx’d with venetoclax + HMA.”

For the article click here.

Source: Naveen Pemmaraju/Twitter

Naveen Pemmaraju holds multiple positions at the University of Texas MD Anderson Cancer Center, including Executive Director of Cancer Medicine, the Director of the Leukemia – Cancer Network, and Professor in the Department of Leukemia. He is also the Director of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) program at the MDACC Leukemia Department. Dr. Pemmaraju’s clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), myeloproliferative neoplasms (MPN) and acute myeloid Leukemia (AML). Dr. Pemmaraju is also a well-known social media influencer.